Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity
Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity
复制标题
利拉鲁肽作为胰岛素附加治疗与增加胰岛素剂量对控制不佳的2型糖尿病和腹型肥胖的中国受试者的疗效和安全性比较
DOI：
10.1186/1475-2840-11-142
复制
发表时间：
2012-11-15
影响因子：
9.3
通讯作者：
Yu, De-min
中科院分区：
文献类型：
--
作者：
Li, Chun-jun;Li, Jing;Yu, De-min
目的：评价在既有胰岛素治疗的基础上加用利拉鲁肽与增加胰岛素用量对控制不良的2型糖尿病合并腹型肥胖者的疗效和安全性。共有84名患者完成了试验，他们被随机分配到添加利拉鲁肽组或胰岛素增高组，同时继续目前的基于胰岛素的治疗。开始应用利拉鲁肽后，胰岛素用量减少0-30%。随后对胰岛素剂量进行了调整，以优化血糖控制。观察两组患者糖化血红蛋白(HbA1c)、血糖、每日胰岛素用量、体重、腰围、降糖事件和不良事件的发生情况。结果：研究结束时，利拉鲁肽组和胰岛素增高组的HbA1c平均降幅分别为1.9%和1.77%(p>；0.05)。然而，达到HbA1c复合终点的受试者百分比
Objective: To assess the efficacy and safety of adding liraglutide to established insulin therapy in poorly controlled Chinese subjects with type 2 diabetes and abdominal obesity compared with increasing insulin dose.Methods: A 12-week, randomized, parallel-group study was carried out. A total of 84 patients completed the trial who had been randomly assigned to either the liraglutide-added group or the insulin-increasing group while continuing current insulin based treatment. Insulin dose was reduced by 0-30% upon the initiation of liraglutide. Insulin doses were subsequently adjusted to optimized glycemic control. Glycosylated hemoglobin (HbA(1c)) values, blood glucose, total daily insulin dose, body weight, waist circumference, and the number of hypoglycemic events and adverse events were evaluated.Results: At the end of study, the mean reduction in HbA1c between the liraglutide-added group and the insulin-increasing group was not significantly different (1.9% vs. 1.77%, p>0.05). However, the percentage of subjects reaching the composite endpoint of HbA1c